Plain-English translation of NCT07026539 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called finerenone to see if it can help protect the kidneys and heart in people with type 2 diabetes who already have kidney disease. Large studies have shown that this medication may slow down kidney disease and reduce heart problems, but those earlier studies didn't include patients taking the newer kidney-protective treatments that are now standard care. This study wants to find out if the medication works well when combined with these standard treatments.
About 40% of people with type 2 diabetes develop chronic kidney disease, which can lead to kidney failure and serious heart problems. Researchers want to understand if this medication can prevent kidney failure when used alongside the treatments patients are already taking, and which mechanisms in the kidney and heart it targets to provide protection.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or a placebo (an inactive pill) for 26 weeks, in addition to your current diabetes and kidney medications. You would visit the study center at the beginning, during the study, and at the end to have blood tests, urine tests, and heart imaging (MRI) to measure how the treatment affects your kidneys and heart. The study is double-blinded, meaning neither you nor the researchers will know which treatment you're receiving until the study ends.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Denmark